PRESS RELEASE
Ho Chi Minh City, 17 January 2025 – STADA Pymepharco – the sole wholly affiliate member of STADA Group (Germany) since 2021, proudly launched the Vietnam Health Report 2024 today at a press conference held at Deutshes Haus Ho Chi Minh. The event was hosted by STADA Pymepharco, in collaboration with the Delegation of German Industry and Commerce in Vietnam (AHK Vietnam), emphasizing the importance of German-Vietnamese partnership in advancing healthcare innovation and quality. This pivotal study evaluates the satisfaction of Vietnamese citizens with the public healthcare system, highlighting the importance of German-Vietnamese collaboration in driving healthcare innovation and quality. The release of this report marks a significant milestone in STADA Pymepharco’s ongoing commitment to improving the health and well-being of the Vietnamese population through innovative healthcare solutions.
The Vietnam Health Report 2024, a part of the annual STADA Health Report series initiated since 2014, which traditionally focuses on healthcare trends in Europe, offering valuable insights into global healthcare dynamics through comparison. This Vietnamese edition, however, provides in-depth analysis into the public sentiment on healthcare quality, accessibility, and affordability in the nation. Surveyed various respondents across six key economic regions of Vietnam, this report offers actionable insights for shaping policies and initiatives for advancing Vietnam’s healthcare system.
Event Highlights and Distinguished Guests
The press conference launching event gathered key leaders and stakeholders from both Vietnam and German public and private sectors, including the leader of Phu Yen Provincial People’s Committee, the leader of the Ministry of Health’s Central Center for Healthcare Communications and Education (T5G), the German Consulate in Ho Chi Minh City, EuroCham, the German Business Association (GBA), leadership of the Vietnamese and German business community, alongside with the esteemed co-host, AHK Vietnam.
H.E. Dao My – Vice Chairman of Phu Yen Provincial People’s Committee, emphasized, “Phu Yen is proud to be home of STADA Pymepharco’s two EU-GMP-certified production sites, which stand as a testament to the province's commitment to fostering innovation and international collaboration. As the most reputable pharmaceutical company in Phu Yen, STADA Pymepharco plays a pivotal role in advancing healthcare standards locally, highlighting Phu Yen's strategic position as a pharmaceutical production hub. Its legacy and achievements also contribute significantly to Vietnam’s global healthcare footprint, showcasing the strength of partnerships in driving progress”.
Dr. Josefine Wallat – German Consul General to Vietnam, commended STADA Pymepharco’s efforts, stating, “The Vietnam Health Report exemplifies the fruitful collaboration between Germany and Vietnam in healthcare. By integrating German expertise with local insights, STADA Pymepharco is playing a vital role in addressing healthcare challenges and improving patient outcomes”.
Mr. Philippe Gautron – General Manager of STADA Pymepharco emphasized, “This report reflects our commitment to bringing ‘German standards’ to Vietnam’s healthcare sector. We aim to serve as a bridge for global innovation, ensuring access to high-quality healthcare for the Vietnamese people. With a strong ambition to expand our reach beyond Vietnam and establish a significant presence in global markets, especially in Europe, we remain steadfast in our commitment to delivering German-standard healthcare. Our 2 EU-GMP-certified production sites, combined with the dedication of our 1,500+ employees, position us as a trusted partner in improving health outcomes. As we embark on this exciting chapter, our vision is clear: to build on our legacy of quality and innovation, strengthen collaborations, and bring affordable, high-quality medicines to more communities around the world. Together, we are shaping a future where healthcare knows no borders”.
Mr. Peter Kompalla – Chief Representative of AHK Vietnam highlighted, “STADA Pymepharco’s initiatives demonstrate the strength of German-Vietnamese comprehensive partnership and economic ties. By fostering collaboration, we can unlock new opportunities to enhance healthcare quality and accessibility to high-quality medicines in Vietnam. As a bridge between the German business community and Vietnam, AHK Vietnam remains committed to fostering opportunities that deepen bilateral relations, support companies like STADA Pymepharco in navigating the Vietnamese market, and facilitate business development that contributes to sustainable growth and success”.
These speeches offered unique perspectives on the state of healthcare in Vietnam and the vital role global partnerships play in advancing the sector.
Panel Discussion: Driving Innovation through Partnerships
The event featured an informative panel discussion on the topic of “German Solutions and German-Vietnamese Relations in Enhancing Healthcare in Vietnam”, exploring innovative healthcare solutions from Germany and the collaborative efforts between the two nations to strengthen Vietnam’s healthcare sector and the general socio-economic development.
- Mr. Đào Mỹ, Vice Chairman, Phu Yen Provincial People’s Committee: Highlighted the local government’s role in healthcare development within the province and international collaboration.
- Dr. Josefine Wallat, German Consul General to Vietnam: Discussed how German healthcare models and expertise can address Vietnam’s evolving challenges, with companies like STADA Pymepharco serving as knowledge transfer hubs.
- Representative from the Ministry of Health (MOH): Raising awareness about proactive healthcare is one of the MOH's priorities to enhance community health. The Vietnam Health Report 2024 by STADA Pymepharco offers new perspectives on this field, providing the MOH with valuable information to further promote this initiative in the future. The collaboration between T5G - MOH, and STADA Pymepharco, a "German Standard" company, is expected to yield positive results in proactive healthcare in the near future.
- Mr. Peter Kompalla, Chief Representative, AHK Vietnam: Shared insights on fostering collaborations between German and Vietnamese companies to advance healthcare development.
- Ms. Minh Nguyen, Vice Chairwoman, GBA Vietnam: Discussed German business community’ roles in driving innovation and sustainability in Vietnam’s healthcare sector.
- Mr. Philippe Gautron, General Manager, STADA Pymepharco: Outlined STADA Pymepharco’s vision for enhancing healthcare and strengthening German-Vietnamese partnerships.
Dialogue with the Media
An open dialogue between media representatives and experts from Germany and Vietnam allowed attendees to engage in discussions about healthcare trends, challenges, and opportunities in the country.
STADA Pymepharco’s Commitment to Excellence
The launch of Vietnam Health Report 2024 marks a key moment for STADA Pymepharco as the company embraces its new corporate positioning: Based on our purpose “Caring for people’s health as a trusted partner”, our aim is to provide “German standard” healthcare in Vietnam and to the world. This commitment underscores the company’s dedication to being a reliable partner in delivering international superior quality healthcare solutions that improve lives. With its global vision of “To be the partner of choice in Generics, Specialty, and Consumer Healthcare, while consistently outgrowing the industry in terms of growth and profitability”, STADA Pymepharco leads in innovation, growth, and industry leadership, creating long-term value for both patients and stakeholders.
The Vietnam Health Report 2024 is expected to serve as a powerful tool for government agencies, healthcare professionals, and private sector stakeholders working to improve the public health system. It also highlights the vital role of international partnerships in shaping the future of healthcare in Vietnam, reinforcing STADA Pymepharco’s continued commitment to deliver impactful healthcare outcomes for the community it proudly serves.
About STADA Pymepharco:
STADA Pymepharco began its journey in 1989 as Pymepharco. In 2021, we officially joined and became the sole wholly affiliate member of STADA Group (Germany) in Vietnam. STADA Pymepharco is one of the leading pharmaceutical manufacturers in Vietnam.
- 2 EU-GMP-certified manufacturing sites in Tuy Hoa, Phu Yen, each with an annual capacity of nearly 1.5 billion units.
- 1200++ employees nationwide working across offices, production sites and sales force nationwide.
- 27,000 SKUs worldwide with 8,000 Consumer Healthcare (CHC) products.
- 400 SKUs in Vietnam – including 250 Generics (Rx) and 150 CHC, of which around 80 products are assessed as bioequivalents to innovator medicines.
- Trusted by 14,000+ customers and partners, including hospitals, pharmacies, and other pharmaceutical businesses.
| |||||||||||||||
Read more about STADA Pymepharco: | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
